Basit öğe kaydını göster

dc.contributor.authorBuyukkaya, Eyup
dc.contributor.authorPoyraz, Fatih
dc.contributor.authorKarakas, Mehmet F.
dc.contributor.authorKurt, Mustafa
dc.contributor.authorAkcay, Adnan B.
dc.contributor.authorAkpinar, Ibrahim
dc.contributor.authorGibson, C. Michael
dc.date.accessioned2020-06-25T18:07:08Z
dc.date.available2020-06-25T18:07:08Z
dc.date.issued2013
dc.identifier.citationclosedAccessen_US
dc.identifier.issn0002-9149
dc.identifier.issn1879-1913
dc.identifier.urihttps://doi.org/10.1016/j.amjcard.2013.03.011
dc.identifier.urihttps://hdl.handle.net/20.500.12587/5492
dc.descriptionWOS: 000322206500008en_US
dc.descriptionPubMed: 23601576en_US
dc.description.abstractAlthough monocyte chemoattractant protein-1 (MCP-1) levels are increased in patients with ST-segment elevation myocardial infarction, the prognostic value of MCP-1 in primary percutaneous coronary intervention (pPCI) is not clear. The goal of the present study was to investigate the association of MCP-1 levels with myocardial perfusion and prognosis in patients with ST-segment elevation myocardial infarction undergoing pPCI. Consecutive pPCI patients (n = 192) were assigned to tertiles according to their admission serum MCP-1 levels. Angiographic no-reflow, Thrombolysis In Myocardial Infarction flow grade, myocardial blush grade, and ST-segment resolution were assessed. Mortality and major adverse cardiac events were evaluated during hospitalization and at the 3-year clinical follow-up visit. Failure of ST resolution was associated with greater admission MCP-1 levels. The risk of no-reflow (Thrombolysis In Myocardial Infarction flow <= 2 or Thrombolysis In Myocardial Infarction flow 3 with final myocardial blush grade <= 2 after pPCI and ST resolution <30%) increased as the admission MCP-1 increased. The 3-year mortality increased as the MCP-1 level increased (8% vs 22% vs 28% for the 3 tertiles, p <0.01). Multivariate logistic regression analysis demonstrated that MCP-1 levels at admission are a significant independent correlate of 3-year mortality in patients with no-reflow as detected by myocardial blush grade. A receiver operating characteristics analysis identified an optimum cut point of >= 254 pg/ml, which was associated with a negative predictive value of 95% in association with 1-year mortality. In conclusion, the plasma MCP-1 levels at admission are independently associated with the development of no-reflow and 3-year mortality in patients with ST-segment elevation myocardial infarction undergoing pPCI. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherExcerpta Medica Inc-Elsevier Science Incen_US
dc.relation.isversionof10.1016/j.amjcard.2013.03.011en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleUsefulness of Monocyte Chemoattractant Protein-1 to Predict No-Reflow and Three-Year Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventionen_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume112en_US
dc.identifier.issue2en_US
dc.identifier.startpage187en_US
dc.identifier.endpage193en_US
dc.relation.journalAmerican Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster